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An unbiased index to quantify 
participant’s phenotypic 
contribution to an open-access 
cohort
Yingleong Chan1,2,3, Michael Tung1,2, Alexander S. Garruss1,2,4, Sarah W. Zaranek5, 
Ying Kai Chan1,2, Jeantine E. Lunshof1,3,6, Alexander W. Zaranek5, Madeleine P. Ball7, 
Michael F. Chou1,2, Elaine T. Lim1,2,8 & George M. Church1,2
The Personal Genome Project (PGP) is an effort to enroll many participants to create an open-access 
repository of genome, health and trait data for research. However, PGP participants are not enrolled for 
studying any specific traits and participants choose the phenotypes to disclose. To measure the extent 
and willingness and to encourage and guide participants to contribute phenotypes, we developed 
an algorithm to score and rank the phenotypes and participants of the PGP. The scoring algorithm 
calculates the participation index (P-index) for every participant, where 0 indicates no reported 
phenotypes and 100 indicate complete phenotype reporting. We calculated the P-index for all 5,015 
participants in the PGP and they ranged from 0 to 96.7. We found that participants mainly have either 
high scores (P-index > 90, 29.5%) or low scores (P-index < 10, 57.8%). While, there are significantly 
more males than female participants (1,793 versus 1,271), females tend to have on average higher 
P-indexes (P = 0.015). We also reported the P-indexes of participants based on demographics and states 
like Missouri and Massachusetts have better P-indexes than states like Utah and Minnesota. The P-index 
can therefore be used as an unbiased way to measure and rank participant’s phenotypic contribution 
towards the PGP.
Whole genome genotyping and sequencing technologies have led to several important discoveries in human 
genetics, and these technologies are now widely used for uncovering the genetic basis in many common and 
rare human traits and diseases1–3. By analyzing genotyping and sequencing data generated from large cohorts of 
individuals, researchers have discovered the genetic variants associated with a variety of complex human traits 
and diseases4–6. These studies typically start with the recruitment of clinical cohorts of patients with one or more 
phenotypes of interests. Then, the patients’ DNA samples are collected and genotyped using whole-genome, 
whole-exome sequencing or whole-genome genotyping using SNP arrays. Some examples of such cohorts include 
the Framingham Heart Study (FHS) and the Atherosclerosis Risk in Communities (ARIC) Cohort, where patients 
are recruited primarily for cardiovascular research7,8. Data from such large cohorts of individuals are condition-
ally available for other researchers and access can be applied through the database of Genotypes and Phenotypes 
(dbGaP)9,10. More recently, projects studies such as the 100,000 Genomes Project aim to perform whole-genome 
sequencing on a large number of individuals with rare diseases, infectious diseases or cancer11.
However, one limitation of these studies with large cohorts of individuals is the ability to re-contact these 
participants for additional phenotypic data that were not assayed during the study, or for follow-up studies based 
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on the genetic discoveries. This is because most of these studies recruited patients that were not consented to be 
re-contacted. In a recent large-scale study that looked at 589,306 individuals, the researchers discovered 13 adults 
with mutations for severe Mendelian diseases and postulated that it will be beneficial to study these 13 resilient 
individuals for therapeutic purposes. However, these 13 individuals were not allowed to be re-contacted because 
of the lack of consent12.
The Harvard Personal Genome Project (PGP) was developed to overcome such a limitation with studies as 
described above13–15. The PGP invites members of the public to volunteer as participants for genetic research, and 
aims to perform whole-genome sequencing on every participant. In turn, each participant contributes his or her 
sequence data along with phenotypic information (such as from their medical records) to the project. To do so, 
participants can log into their PGP public profile at their own convenience, upload their phenotypic information 
and perform various survey questionnaires. The data is then made open-access, allowing anyone to use the gen-
otype and phenotype data for research, accelerating the process of using data from large cohorts of individuals 
for research16. These participants have consented the public sharing of their genotype and phenotype data for 
research purposes, and can be re-contacted for additional follow-up study. Moreover, the PGP does not restrict 
the inclusion of participants based on a specific medical condition or disease, thus allowing access to a broad 
repository of individuals with various traits and conditions. However, while participants can choose to participate 
in the survey questionnaires provided by the PGP and also have the option of providing additional phenotype 
data, it is unclear how much phenotype data is actually available and how many participants freely participated in 
providing information for those phenotypes.
In this study, we explored the landscape of phenotypes available in the PGP and how extensive they are using 
a scoring algorithm, which is unbiased towards any particular phenotype. This algorithm scores both the pheno-
types and participants. Briefly, a point is awarded to each phenotype for every unique participant that provided 
a valid value for that phenotype. For example, if the phenotype is “lung cancer”, valid values include “yes” and 
“no”. The total number of points for each phenotype is the Phenotype Score. The Phenotype Score for all valid 
phenotypes provided by the participants are then added up to calculate the score for each participant. This score 
is divided by the theoretical maximum score, i.e. the total sum of all valid Phenotype Scores, multiplied by 100, 
which results in a number ranging from 0 to 100. We term this number as the Participation-index (or P-index), 
which gauges the extensiveness in which the participant provided valid phenotypes to the PGP. In determining 
the P-index, the algorithm allocates more weight to phenotypes that are provided by many participants and gives 
less weight to phenotypes that are provided by only fewer participants. This is because having more participants 
with a specific phenotype increases the statistical power for discovering a meaningful genetic association17–19. 
This would encourage participants to prioritize contributing phenotypes that other participants have already 
contributed. We find that most of the high scoring phenotypes are phenotypes found in the survey questionnaires 
provided by the PGP. In addition, most participants have either high P-indexes (P-index > 90) or low P-indexes 
(P-index < 10). We also find that while there are significantly more male than female participants (Nmales = 1,793, 
Nfemales = 1,271, P = 1.96 × 10−21), females on average have higher P-indexes than men (median P-indexmale = 75.9, 
median P-indexfemale = 88.1, P = 0.015). We also formulated a quantitative trait P-index (QtP-index), which meas-
ures the contribution of participants with respect to a list of quantitative traits like height and weight. Finally, we 
partitioned the participants demographically and reported their P-indexes based on states and zip codes. Thus, 
using this scoring algorithm, we investigated the landscape of phenotype data available in the PGP, as well as 
the willingness of participants in providing phenotype data. Our algorithm can be used to incentivize and guide 
participants (See Discussion) in sharing more phenotype data and can also be applied to other projects similarly 
structured like the PGP in reaching out to participants for sharing phenotypes.
Results
Most high scoring phenotypes were contributed by participants answering survey question-
naires. We first captured all the participants’ data from the PGP (Table S1), for a total of 5,015 participants and 
scored each phenotype based on the number of participants who have shared information on the phenotype (see 
Materials and Methods). Out of the 10,604 unique phenotypes, a total of 2,609 were considered valid based on our 
filtering criteria (Table S2). Phenotypes were considered valid if 2 or more participants reported valid values for 
that phenotype, if the phenotype does not pertain to genotyping information and if they meet our other filtering 
criteria (see Materials and Methods). Out of the valid phenotypes, 262 of these (10.0%) had a score greater than 
1,000, indicating that more than 1,000 individuals volunteered information on these phenotypes and 281 (10.8%) 
had a score greater than 100. The top 50 phenotypes had scores ranging from 1,845 to 3,080 (Fig. 1). Sex/gender 
was the highest-scoring phenotype, followed by information about ancestry and various diseases, such as breast 
and colon cancer. All the top 50 phenotypes were directly queried from survey questionnaires. There are 17 differ-
ent surveys of which 15 are generally available to all participants (Table 1). While most participants provided valid 
values for these phenotypes by answering the survey questionnaires, there were some participants that provided 
valid values for them as part of their medical record. The highest scoring phenotype that was not from any survey 
questionnaires was “diastolic blood pressure” with a score of 250.
Disease prevalence rates estimated from PGP participants. As most of the phenotypes participants 
provided were from the survey questionnaires, we proceed to determine the disease incidences for phenotypes 
found in 10 survey questionnaires, a total of 239 unique phenotypes (Table S3). The disease with the highest 
prevalence among the PGP participants was “Dental cavities” followed by “Myopia (Nearsightedness)” with more 
than half the cohort afflicted (79.83% and 53.5% respectively) (Table S4). Other phenotypes with high prevalence 
include acne, astigmatism, canker sores, urinary tract infection and dandruff (Table S4). Based on our knowledge 
of some of the diseases listed, some seem to be less common among the PGP participants than the reported pop-
ulation prevalence while some seemed to be higher. For example, the incidence of diabetes mellitus, type 2 in the 
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PGP is 16 out of 1,845 (0.87%) while the reported prevalence ranged from 5% to 14%20–22. On the other hand, the 
incidence of Marfan syndrome in the PGP is 4 (unrelated) individuals out of 1,768 (0.23%) while the reported 
prevalence ranged from 0.01% to 0.03%23.
Ranking of participants using the Participation-index (P-index). We next calculated the P-index 
of every participant in the PGP (Table S5). The majority of these participants were of European ancestry, with 
2,644 (86.0%) listing their race/ethnicity as “White” (Table S1). The top 10 ranking participants had P-indexes 
greater than 96.36 (Table 2). The top-ranked participant (hu96713F) had a P-index of 96.735 while the next 
highest-ranked participants (hu6D1115 and hu199EF4) had P-indexes of 96.716 and 96.603 respectively (Table 2). 
Given that none of these top-ranking participants have P-indexes of 100, they can provide more phenotypes to 
improve their P-indexes. For example, hu6D1115 (rank 2nd), can provide a valid phenotype for “can recognize 
musical intervals” (1,843 points), “diastolic blood pressure” (250 points) or “systolic blood pressure” (249 points), 
either of which would propel her into the 1st rank.
Out of the 5,015 participants, 1,350 participants have a score of 0, indicating that over a quarter of the partic-
ipants (26.9%) did not provide any valid phenotypes about themselves (Fig. 2). The median P-index is 6.79 and 
if we filter away the 1,350 participants with no phenotypes, the median P-index goes up to 33.76. The participant 
scores are mostly dichotomized into 2 distinct groups. Most participants either have P-indexes above 90 (1478 
participants) or P-indexes below 10 (2900 participants). These 2 groups of participants make up 87.3% of all par-
ticipants in the PGP (Fig. 2). As the high-scoring phenotypes are from the survey questionnaires, this implies that 
most participants either answer most of the surveys or do not take any them, which can explain for the dichotomy 
of the P-indexes.
Females tend to share more phenotype data than males. Out of the 3,080 individuals who shared 
their sex/gender, 1,793 of them (58.2%) were males, 1,271 (41.3%) were females and 16 (0.5%) were non-binary 
or listed both male and female as their gender (Table S6). If we assume under the null hypothesis that males 
are as likely to participate in the PGP as females, there were significantly more males than females (binomial 
P = 1.96 × 10−21). Overall, females have on average higher P-indexes than males (Wilcoxon rank-sum P = 0.015, 
Fig. 3). The median P-index for males is 75.89 while the median P-index for females is 88.09. There were propor-
tionally fewer females with P-index less than 10 (37.0% males versus 31.9% females) and proportionally more 
females with P-index greater than 90 (46.1% males versus 49.0% females).
Quantitative trait P-index (QtP-index) to assess and encourage participants to contribute 
quantitative traits. Some of the phenotypes contributed by PGP participants are quantitative, i.e. they 
have numerical values. To encourage and guide participants to contribute quantitative traits, we formulated an 
Figure 1. Top 50 phenotypes with the highest Phenotype Score. The Phenotype Score indicates the number of 
unique participants with valid values for that phenotype.
www.nature.com/scientificreports/
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alternative measure which we call the quantitative trait P-index (QtP-index). Similar to the P-index, we selected 
88 quantitative phenotypes (Table S7) and calculated the QtP-index based as well as participant’s ranking based 
on these 88 phenotypes (Table S8). The top-ranked participant (hu96713F) had a QtP-index of 87.34 and is also 
the top-ranked participant of the P-index ranking (Table 2). However, none of the other top 10 participants over-
lapped with the top 10 ranked participants using P-index (Table 2).
Stratifying the P-index based on geographic location. We next explored the scores of participants 
based on geographic location. 2,780 participants reported the states in which they reside in (Table S9). We sep-
arated the participants into their respective states and filtered for states that had at least 30 participants, which 
resulted in 26 states. We then calculated the median P-index as well as the percentage of participants in these states 
Survey #Phenotypes #Participants
PGP10 Trait Survey 23 10
2011 PGP10 CAGI Survey 34 9
PGP Participant Survey 13 2941
PGP Trait & Disease Survey 
2012: Blood 13 1794
PGP Trait & Disease Survey 
2012: Cancers 25 1898
PGP Trait & Disease Survey 
2012: Circulatory System 28 1716
PGP Trait & Disease Survey 
2012: Congenital Traits and 
Anomalies
22 1768
PGP Trait & Disease Survey 
2012: Digestive System 23 1724
PGP Trait & Disease Survey 
2012: Endocrine, Metabolic, 
Nutritional and Immunity
18 1839
PGP Trait & Disease Survey 
2012: Genitourinary Systems 15 1687
PGP Trait & Disease Survey 
2012: Musculoskeletal System 
and Connective Tissue
23 1724
PGP Trait & Disease Survey 
2012: Nervous System 22 1773
PGP Trait & Disease Survey 
2012: Respiratory System 9 1697
PGP Trait & Disease Survey 
2012: Skin and Subcutaneous 
Tissue
16 1746
PGP Trait & Disease Survey 
2012: Vision and hearing 25 1843
PGP Basic Phenotypes Survey 
2015 9 615
Absolute Pitch Survey 4 2583
Table 1. The various surveys made available to participants along with the number of phenotypes for each 
survey and number of participants that participated in each survey.
HUID P-index Rank HUID QtP-index Rank
hu96713F 96.74 1 hu96713F 87.34 1
hu6D1115 96.72 2 hu016B28 84.03 2
hu199EF4 96.60 3 huF9E138 83.23 3
huC73C2D 96.53 4 huEAA391 82.61 4
hu925B56 96.53 5 hu88A920 82.57 5
hu8BEDE1 96.49 6 hu4C04A0 82.36 6
hu3E50D4 96.42 7 hu7FC65B 82.07 7
hu155D20 96.38 8 huFF6AB4 81.86 8
huF421B2 96.37 9 huD50D1C 81.58 9
huDD6E7A 96.37 10 hu56B3B6 81.45 10
Table 2. The top 10 ranking participants using P-index (all valid phenotypes) and QtP-index (88 quantitative 
phenotypes). HUID indicates the PGP ID, which is a unique identifier for every participant of the PGP.
www.nature.com/scientificreports/
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that have P-indexes > 90. Overall, Missouri and Massachusetts performed the best, where the median P-indexes 
are well over 90 and greater than 60% of the participants has P-indexes > 90 (Fig. 4, Table S10). The state with 
the lowest median P-index is Minnesota with a median P-index of 8.17. South Carolina has the least number of 
participants with P-indexes > 90; only 29% of the participants (9 out of 31) had P-indexes > 90 (Fig. 4, Table S10). 
We also analyzed the P-indexes of participants stratified by zip code. While 2,556 participants provided zip codes 
(Table S2), only 2,538 were valid to be linked to actual longitude and latitude coordinates (Table S11). We clus-
tered these 2,538 participants into 354 distinct clusters and plotted their median P-indexes (see Materials and 
Methods). We observed a similar trend as the analysis by state, where the hotspots with participants having high 
P-indexes are in Massachusetts, Missouri and California (Fig. 5).
Discussion
The use of a ranking system to rate individuals and institutions is commonly done in many different fields like 
academia, politics, sports, etc. In academia, we have ranking systems for scientific journals like the impact fac-
tor24, ranking systems for universities25 as well as ranking of individual scientists using the h-index26. A common 
purpose for all ranking systems is act as a performance indicator as well as an incentive for its players to improve 
their rankings. In this manuscript, we described a method for ranking phenotypes and participants in databases 
used for research and applied the method to the Harvard Personal Genome Project (PGP). The key feature of the 
method is that it awards each phenotype a score equal to the number of unique participants that reported a valid 
value for that phenotype. The rationale for doing so is because the more participants with similar phenotypes, the 
more statistical power for detecting genetic variants associated with that phenotype17–19. Overall, there seems to 
be an under reporting of potential phenotypes even though there are some high scoring participants. Common 
anthropometric measurements like height and weight had a phenotypic score of only 1,507 and 1,598 respectively 
which implies that only a quarter of the participants reported those phenotypes. For the 1,350 participants who 
had a score of 0, they could bump their P-indexes above 90 by participating in all the available survey question-
naires, which highlights the importance of these survey questionnaires towards obtaining a high P-index.
The algorithm for ranking participants could be adjusted in several ways for measuring the participant’s activ-
ity in a more specific manner. A simple adjustment could be to use only a selected number of phenotypes to 
perform the ranking or to give extra weight to some phenotypes, making the ranking algorithm biased toward 
theses phenotypes. For example, if one wants to measure or incentivize the participant’s value for cardiovascular 
research, only phenotypes pertaining to cardiovascular properties like weight, heart rate, cholesterol levels, etc 
could be used or given more weight in the ranking. In our case, we implemented an alternative P-index called the 
quantitative P-index (QtP-index) to assess the contribution of participants toward certain quantitative traits. Also, 
the current algorithm ignores repeated measurement of the same phenotype but one can adjust the algorithm to 
give extra points to participants for providing multiple measurements of the same phenotypes suitable for the 
use in longitudinal research studies. Another adjustment could be to have an automated way to combine similar 
phenotypes together as a single phenotype. For example, in the PGP, the phenotype of “systolic blood pressure” 
is also sometimes represented as “blood pressure, systolic (upper number)”, “systolic pressure” or “systolic”. By 
the use of automated text processing, it is possible to reconcile such similar phenotypes to a single phenotype and 
score the participants with the reconciled phenotype. While these adjustments can improve the ranking system, 
the current method as described is the first step towards an unbiased and robust ranking mechanism for tracking 
the phenotypes available and measuring the participation rate of the PGP participants.
There are some other benefits for ranking of participants and phenotypes in databases like the PGP. Besides 
incentivizing participants to upload as much phenotypes as possible or to determine the possible phenotypes to 
study, rankings can be used to prioritized participants if the need arises. As participants with rich phenotypes are 
more useful for research when combined with genotype and biomaterial availability, the rankings can be used to 
prioritized participants for sequencing and banking of cells. The participant’s ranking could also be used for the 
Figure 2. The distribution of the Participation index (P-index) for all participants of the PGP, sorted with 
higher scoring participants on the left and lower scoring participants on the right. 
www.nature.com/scientificreports/
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purposes of rewarding highly contributing participants by providing them with some reward, e.g. attendance to 
conferences, consultation about their genomes, etc.
However, there might be potentially some drawbacks in performing the rankings. It could provide an incen-
tive for participants to lie about their phenotypes or to upload phenotypes that have no value and its only purpose 
is to boost the participant’s ranking (junk phenotypes). However, there are several reasons why this would not 
be problematic. First, participants are scored not for having the phenotype but for having a valid value or entry 
for that phenotype. For example, if the phenotype were “Diabetes Mellitus, Type 2”, participants with diabetes 
will be scored similarly to participants without diabetes if they declared their diabetes status (either yes or no), 
somewhere in their public profile. Therefore, in this case, lying about the one’s phenotype does not improve your 
P-index. Next, while participants can upload junk phenotypes in a quest to improve their scores, since only phe-
notypes with scores greater than 1 will be used, these phenotypes would be irrelevant unless another participant 
Figure 3. Comparing the P-index of males versus females. (A) The P-index boxplots for male and female 
participants. The female P-index is significantly higher than the male P-index (Wilcox rank-sum, P = 0.015). (B) 
The comparison of the P-index distribution between male and female participants normalized by the number of 
participants for each gender.
www.nature.com/scientificreports/
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Figure 4. The P-index based on state. Only states with 30 or more participants were included. (A) Box-plot of 
P-index of participants from each state. (B) P-index dot-plot of participants from each state.
Figure 5. P-indexes by region based on zip codes clustered into 354 distinct groups. The color indicates 
the median P-index of each group while the size of the circles indicates the number of participants for each 
group. Figure was generated using R version 3.1.1 (https://www.r-project.org/) and package ‘ggmap’ (Google 
roadmaps) for the map and package ‘ggplot2’ for plotting27,28.
www.nature.com/scientificreports/
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uploads the same phenotype. Thus, cases for such misdemeanor would be rare, as it would require collusion with 
another participant. Furthermore, the cutoff score could always be adjusted upwards if this indeed becomes a 
problem.
Also, the PGP is unlike a traditional cohort where phenotypes are contributed by participants online. The 
argument could be made that the accuracy of the phenotypes contributed, especially for those provided by the 
survey questionnaires are less accurate than that of a traditional medical cohort. Indeed, for most of our disease 
surveys, participants are presented with an online form in which they are presented with a list of diseases and 
conditions and they place a check next to the disease that they are afflicted with. As such, if participants place a 
check on the wrong box, or fail to place a check on the right box, the surveys will erroneously report wrong values 
for the phenotypes submitted. There could be ways to mitigate such error like having the system perform error 
checking or to have the participants reconfirm their phenotype status before submitting the surveys. However, 
given the open-access, open-consent nature of the PGP, participants can always be re-contacted to confirm their 
submitted phenotypes.
In summary, we have developed a method to compute the scores of participants and phenotypes in a database 
for epidemiological and genetic association studies. We applied the method to the Harvard Personal Genome 
Project (PGP), which returns the score of every phenotype and the P-index of every participant. The phenotype 
score indicates the number of participants with a valid entry for that phenotype and can be used as a guide for 
filtering potential phenotypes for research. The participant’s P-index gives an estimate of the overall comprehen-
siveness of the participant’s phenotypic profile in the PGP and can be also be used to incentivized participants to 
make their phenotypic profile more comprehensive. Ranking the participants may provide a useful measure with 
which to compare, in an unbiased way, different participants of the PGP and that ranking can be used as a basis 
for prioritizing participants for research. Finally, the P-index can be use in a participant-driven cohort like the 
PGP to study the extent to which participants are willing to share their phenotypic data and evaluate the strengths 
and weaknesses of such a cohort compared to a traditional population cohort.
Materials and Methods
Ethics statement. The Harvard Personal Genome Project (PGP) study is conducted according to the prin-
ciples expressed in the Declaration of Helsinki. Participation is voluntary and each participant gave informed 
consent to make their data publicly available. Participants make their data available at their own discretion. All 
methods presented were carried out in accordance with relevant guidelines and regulations. Experimental and 
study protocols were approved by Harvard University (Human Research Protection Program).
Participant recruitment. The Harvard PGP recruit participants via an online sign up page. Participants 
must pass an online quiz, which they can perform as many times as they want to correctly answer all the ques-
tions. The purpose of the quiz is to educate the participant on the benefits and risks of having their genomes, 
phenotypes and cell lines available publicly. The details of this process can be found on our webpage (http://www.
personalgenomes.org/harvard/howitworks) and have been previously described in other publications14,15.
Algorithm for scoring phenotypes and participants. The method calculates points for every pheno-
type and every participant within the database. A phenotype is any data type that any participant uploaded to the 
database. For example, phenotypes could be “height”, “weight”, “type 2 diabetes” and their values could be “5 feet 9 
inches”, “140 lbs” and “yes” respectively. Let F be the list of valid phenotypes and P is the list of participants. First, 
the method calculates the score for every unique phenotype. Each unique phenotype is given a score equal to the 
number of participants with a valid value of that phenotype, i.e.
∑=
=







where I F P( , )i j  is an indicator function that returns 1 if the participant P j have a valid value for phenotype Fi and 
0 otherwise. N is the total number of participants within the database and Si is the phenotype score for phenotype 
Fi. The Participation-index (P-index) for each participant is then calculated as the sum of phenotype scores (S) 





















where M is the total number of valid phenotypes.
Downloading and parsing data from the PGP. We implemented a python script to automatically cap-
ture all participants’ data from the PGP via its website (https://my.pgp-hms.org/users). We captured the data 
presented here on July 6th, 2016. We iterate through each participant’s profile and extracted every phenotype and 
its corresponding value. Special characters that encodes for html were replaced by their ASCII equivalent. The 
resulting phenotypes and their values are stored and formatted in a tab-separated file.
Survey normalization process. For some of the surveys, only the phenotypes that the participants 
answered “yes” to are listed on their public profile. For example, for the survey “PGP Trait & Disease Survey 2012: 
Blood”, there are 13 phenotypes or conditions listed for that survey (Table S3). However, if a participant took the 
survey but answered no to any of the phenotypes, that information is not listed on the participant’s public profile. 
As such as part of the normalization process, we reformatted the earlier tab-separated file to fill in the missing 
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phenotypes to indicate that the participants have answered “no” to the phenotypes or conditions listed on the 
survey (Table S1). We also replaced synonymous phenotypes within the surveys with the same phenotype name. 
As such, “1.3 --- Weight” was replaced with “Weight”, 1.2 --- Height” was replaced with “Height”, “1.1 --- Blood 
Type” was replaced with “Blood Type”, “Race” was replaced with “Race/ethnicity”, “Gender” was replaced with 
“Sex/Gender” and “Date of Birth (mm/dd/yyyy)” was replaced with “Date of Birth”. A list of surveys generally 
available to PGP participants can be found at https://github.com/PGPHarvard/pgp-surveys/tree/master/Surveys.
Scoring phenotypes from the PGP. We implemented a script that is calculates the phenotypes scores by 
implementing the algorithm for scoring as described above. The script takes in the tab-separated file processed 
earlier (Table S1) and calculates the score for each phenotype by iterating through every individual. The script 
ignores multiple entries of the same phenotype for each participant and counts them only once. For each partic-
ipant, the script excludes phenotypes with invalid values. Invalid values are values deemed to be ambiguous and 
have no potential value for research. These values are “unsure”, “not applicable”, “other/don’t know/no response”, 
“no response”, “not sure” and “unspecified”.
Calculating the P-index (scoring participants) from the PGP. The phenotype scores calculated earlier 
were used as input to another script, which calculates the participant’s P-index using the algorithm described 
above. We omitted several phenotypes from the P-index calculation that we deem not to be true phenotypes. 
Phenotypes like “enrolled”, “consent”, “account created”, “eligibility screening”, “participant id” and “exam” have a 
score of 5,015, indicating that these phenotypes are generated by default for every participant in the PGP regard-
less of whether they provided any true phenotypes and therefore excluded (Table S2). Phenotypes that pertain to 
the participant’s genotype were also excluded. These are phenotypes that are deemed to be information about the 
participant’s genome, i.e. whole-genome sequencing data, whole-exome sequencing data, whole-genome geno-
typing data, etc (Table S2). On top of that, we also excluded phenotypes with a phenotype score of 1, i.e. the phe-
notype is not shared by anyone else. This filtering left us with a total of 2,609 valid unique phenotypes that were 
included for calculating the P-index for every participant (Table S2).
Calculating the quantitative trait P-index (QtP-index). The quantitative trait P-index (QtP-index) 
is calculated in the same way as the P-index but using only a list of phenotypes that have quantitative values. We 
used only quantitative traits that have a phenotype score greater than or equal to 10, which resulted in 88 such 
phenotypes (Table S7).
Calculating median P-indexes by zip code. Out of the 5,015 PGP participants, 2,556 had provided zip 
code values. The R package ‘zipcode’ was used to clean and filter for valid zip codes that can be linked to latitude 
and longitude coordinates, resulting in a final dataset of 2,538 participants (Table S9). Participant locations were 
rounded to the nearest degree by taking the floor of the latitude and ceiling of the longitude and grouped accord-
ing to their rounded coordinates, resulting in 354 groups. Each group was counted to determine the number of 
participants and the median P-index. The coordinates used to plot each data point were the median, unrounded 
latitude and longitude for each group. Map images were obtained using the R package ‘ggmap’ using Google road-
maps and plotted with R package ‘ggplot2’27,28.
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